Pancreatic Cancer
Pancreatic cancer is one of the deadliest cancers worldwide, with survival rates remaining very low.
On This Page:
Overview
Pancreatic cancer begins in the pancreas, an organ deep in the abdomen that helps with digestion and blood sugar regulation. Most cases are pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form that is often diagnosed at a late stage.
Pancreatic cancer is challenging to detect early because symptoms usually appear only after the cancer has grown or spread. Risk factors include age, smoking, chronic pancreatitis, obesity, family history, and certain genetic mutations.
Traditional treatments include surgery, chemotherapy, and radiation, but survival rates for pancreatic cancer remain low. Immunology research, however, is opening new possibilities, with scientists seeking ways to overcome the tumor’s defenses and help the immune system recognize and attack pancreatic cancer.
Key Points
- Pancreatic cancer is one of the deadliest cancers worldwide, with survival rates remaining very low.
- Immunotherapy has had limited success so far, but new strategies are emerging to make pancreatic tumors more visible to the immune system.
- New approaches, including cancer vaccines and cell-based therapies, are being developed to activate the immune system and extend survival.
Key Statistics (U.S.)
Key Statistics
Global incidence: Around 510,000 new cases and 467,000 deaths in 2022.
U.S. incidence: In 2025, about 67,440 new cases of pancreatic cancer will be diagnosed. Pancreatic cancer is expected to cause about 51,980 deaths during 2025.
Immunology and Pancreatic Cancer
Pancreatic cancer has proven especially difficult for immunotherapy, in part because pancreatic tumors are often surrounded by a dense tumor microenvironment (TME) that blocks immune cells from entering and killing cancer cells.
Unlike melanoma or lung cancer, checkpoint inhibitors (like pembrolizumab and nivolumab) have shown benefit only in a small subset of pancreatic cancers, specifically those with MSI-H (microsatellite instability-high) or dMMR (mismatch repair-deficient) status. For these patients, checkpoint blockade can sometimes produce strong, long-lasting responses.
What’s next for pancreatic cancer?
The future of pancreatic cancer treatment lies in immunotherapy combination approaches and more personalized strategies. Scientists are working to:
- Combine checkpoint inhibitors with chemotherapy, radiation, or vaccines to help “prime” the immune system.
- Targeting the tumor microenvironment, reducing the fibrotic barrier that prevents immune cells from reaching the tumor.
- Developing personalized vaccines, including mRNA-based vaccines tailored to each patient’s tumor mutations.
- Identify biomarkers to determine which patients are most likely to respond to immunotherapy.
Though pancreatic cancer remains one of the toughest cancers to treat, immunology-driven research is providing new hope that the immune system can be mobilized against this challenging disease.
Sources
- Pancreatic Cancer Statistics, World Cancer Research Fund
- Key Statistics for Pancreatic Cancer, American Cancer Society
- Immunotherapy for Pancreatic Cancer, American Cancer Society
Related Topics
Downloads
External Resources
Latest News
